ACE2 News and Research

RSS

Potential therapy candidates for patients infected with the SARS-CoV-2 Omicron variant

Researcher discusses several promising therapeutic candidates that have been proposed for the treatment of patients infected with the Omicron variant.

28 Jan 2022

Study demonstrates minimally invasive, aerosolized vaccine candidate to combat SARS-CoV-2

This study showed inhalable Covid-19 mimetic particle carriers as potential, versatile, aerosolizable COVID-19 vaccine candidates if worked on with continued optimization and refinement.

28 Jan 2022

Exploring receptor-blocking conserved non-neutralizing antibodies for SARS-CoV-2 therapy

In a new study, researchers hypothesized and developed broad-spectrum SARS-CoV-2 inhibitors, ReconnAbs, by modifying the existing non-neutralizing antibodies targeted towards the highly conserved epitopes of the SARS-CoV-2 spike (S) protein combined with a receptor-blocking component.

28 Jan 2022

E406W mutation on SARS-CoV-2 RBD escapes monoclonal antibody cocktail-mediated neutralization

Researchers look to better understand the molecular basis of E406W-mediated escape from the REGEN-COV cocktail and cilgavimab.

28 Jan 2022

Scientists identify immunogens that can elicit antibody responses against multiple SARS-CoV-2 variants

In a new study, researchers identified conserved sites in the SARS-CoV-2 spike protein using structural and sequence data, and then combined the results with existing deep mutational scanning data to design six antigens that can offer protection against significant immune escape mutations in the SARS-CoV-2 receptor-binding domain.

27 Jan 2022

Targeting CHI3L1 inhibits SARS-CoV-2 variants, including Delta and Omicron

Researchers show that the CHI3L1 inhibitors reduce epithelial cell infection by SARS-CoV-2 VOC pseudovirus moieties.

27 Jan 2022

Omicron RBD mutations increase ACE2 binding and reduce antibody sensitivity

In a study conducted at the Florida International University, USA, scientists have investigated the impact of spike receptor-binding domain (RBD) mutations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant on its interaction with human angiotensin-converting enzyme 2 (ACE2).

26 Jan 2022

Alterations of sphingolipids and their metabolizing enzymes in hospitalized or convalescent COVID-19 patients

An interdisciplinary team of researchers from Europe analyzed the alterations of sphingolipids and their metabolizing enzymes in hospitalized or convalescent COVID-19 patients.

26 Jan 2022

SARS-CoV-2 Omicron variant found to display increased resilience to antiviral type I interferon response

In a new study, scientists have compared the Omicron variant with the Delta VOC (B.1.617.2) as well as the wildtype strain (B.1), with respect to their interaction with the antiviral type 1 interferon response in infected cells.

26 Jan 2022

Effects of the Omicron spike amino acid changes in the interaction with human ACE2 receptor or human antibodies

A recent study analyzed the effects of the interaction between SARS-CoV-2 Omicron spike amino acid and the human ACE2 receptor or with human antibodies.

26 Jan 2022

Anti-SARS-CoV-2 antibodies found in wild mustelids in France

A new study focused on the identification of SARS-CoV-2 infection in wild mustelids in the French region of Brittany.

26 Jan 2022

Cannabidiol inhibits SARS-CoV-2 replication in human cells and mice

In research recently published in the journal of Science Advances, an interdisciplinary team of researchers from the University of Chicago assessed the potential role of cannabidiol (CBD), a natural product extracted from the cannabis plant, to prevent and inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in human cells and mice.

26 Jan 2022

ACE2 News and Research

Potential therapy candidates for patients infected with the SARS-CoV-2 Omicron variant

Study demonstrates minimally invasive, aerosolized vaccine candidate to combat SARS-CoV-2

Exploring receptor-blocking conserved non-neutralizing antibodies for SARS-CoV-2 therapy

E406W mutation on SARS-CoV-2 RBD escapes monoclonal antibody cocktail-mediated neutralization

Scientists identify immunogens that can elicit antibody responses against multiple SARS-CoV-2 variants

Targeting CHI3L1 inhibits SARS-CoV-2 variants, including Delta and Omicron

Omicron RBD mutations increase ACE2 binding and reduce antibody sensitivity

Alterations of sphingolipids and their metabolizing enzymes in hospitalized or convalescent COVID-19 patients

SARS-CoV-2 Omicron variant found to display increased resilience to antiviral type I interferon response

Effects of the Omicron spike amino acid changes in the interaction with human ACE2 receptor or human antibodies

Anti-SARS-CoV-2 antibodies found in wild mustelids in France

Cannabidiol inhibits SARS-CoV-2 replication in human cells and mice

Spike-mediated CFTR inhibition accounts for airway inflammation in COVID-19

Development of synthetic molecules that can bridge T cells with SARS-CoV-2 infected cells

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

Impact of clustered mutations in SARS-CoV-2 Omicron spike function

Characterization of unique pathogenesis of SARS-CoV-2 Delta variant in mouse model

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Researchers discover mechanism behind SARS-CoV-2 entry into the brain

Researchers are in the race to beat Omicron

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News